PTEN and prostate cancer: Jansson and coworkers have used prostate cancers developing in PTEN/TP53 null mice to perform a high-throughput analysis of a large panel of drugs and reached the conclusion that HSP90 inhibitors are among the most active compounds and have clinical potential for use in drug combinations to enhance the efficacy of current drugs and to delay the occurrence of resistance [669].